// App-Quantinova.ai

PB1565 : A PHASE III TRIAL (GO42909) EVALUATING MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE (M-LEN) VERSUS RITUXIMAB-LENALIDOMIDE (R-LEN) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Researchers

Presenter

  • Christian W. Scholz

Principal Investigators

  • Nancy L. Bartlett

  • Loretta Nastoupil

  • Michael C. Wei

  • Carol OHear

  • Andrea Knapp

  • Catherine Granier

  • Song Pham

  • Kati Sarouei

  • Chi-Chung Li

  • Alessia Bottos

  • Enkhtsetseg Purev

  • Franck Morschhauser

Medical Centers

  • F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Department of Medicine,Washington University School of Medicine ,St. Louis,United States

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Department of Hematology and Oncology,Vivantes Klinikum Am Urban,Berlin,Deutschland

  • Hopital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lillie, France

  • Genentech Inc., San Francisco, United States

Locations

  • United Kingdom

  • Switzerland

  • United States

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Cytokine release syndrome

  • Follicular lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Controlled

  • Cohort

Phase

  • III

Study Id's

  • NCT02500407

  • NCT04712097

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved